LncRNA AC099850.3 Promotes Hepatocellular Carcinoma Proliferation and Invasion Through PRR11/PI3K/AKT Axis and is Associated with Patients Prognosis

Overview

Journal J Cancer

Specialty Oncology

Date 2022 Feb 14

PMID 35154469

Authors

Fangjing Zhong

Sheng Liu

Donghai Hu

Liwen Chen

Affiliations

Soon will be listed here.

Abstract

LncRNA is a key factor influencing tumor development. The present study aimed to investigate the effect of a novel lncRNA on the progression of hepatocellular carcinoma (HCC). A candidate lncRNA in The Cancer Genome Atlas database was identified using limma and survival R packages. The effect of lncRNA AC099850.3 on cell proliferation, apoptosis, migration, and invasion, as well as its association with immune cells in HCC were investigated. Furthermore, the functional mechanisms of lncRNA AC099850.3 in HCC were elucidated. The aberrant expression of lncRNA AC099850.3 was identified in tumor tissues and its prognostic relevance in HCC was determined. The results revealed that AC099850.3 was highly expressed in HCC tissues and cell lines, and it predicted poor prognosis in patients with HCC. Furthermore, knockdown of AC099850.3 significantly suppressed the proliferation and metastatic potential of HCC cells, and promoted cell apoptosis in HCC cells. The results of gene set enrichment analysis revealed that the PI3K/AKT pathway was associated with the biological function of AC099850.3, which was further validated by western blotting. was identified as the target gene of AC099850.3 and we established that AC099850.3 acted as an oncogene in the PRR11/PI3K/AKT axis. Immune cell infiltration analyses results revealed that AC099850.3 was positively correlated with T follicular helper cells, M0 macrophages, CD4 memory T cells, and memory B cells. Conversely, AC099850.3 was negatively correlated with M2 macrophages, monocytes, natural killer cells, and CD8 T cells, which could be responsible for its oncogenic effect. Of note, a significantly positive correlation was observed between AC099850.3 and key immune checkpoint molecules (PD-1, PD-L1, PD-L2, and CTLA4) in the present study, making AC099850.3 a potential immune therapeutic target for HCC. AC099850.3 can promote malignant biological behavior of HCC cells, and could be a potential biomarker and therapeutic target for HCC.

Citing Articles

Interplay between lncRNAs and the PI3K/AKT signaling pathway in the progression of digestive system neoplasms (Review).

Zhang X, Shi L, Xing M, Li C, Ma F, Ma Y Int J Mol Med. 2024; 55(1).

PMID: 39513614 PMC: 11573320. DOI: 10.3892/ijmm.2024.5456.

Identification and validation of a five-necroptosis-related lncRNAs signature for prognostic prediction in hepatocellular carcinoma.

Chen H, Hou G, Lan T, Xue S, Xu L, Feng Q Heliyon. 2024; 10(18):e37403.

PMID: 39309864 PMC: 11415698. DOI: 10.1016/j.heliyon.2024.e37403.

AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy.

He A, Huang Z, Feng Q, Zhang S, Li F, Li D J Transl Med. 2024; 22(1):809.

PMID: 39217342 PMC: 11366154. DOI: 10.1186/s12967-024-05576-y.

Identification of a novel necroptosis-related LncRNA signature for prognostic prediction and immune response in oral squamous cell carcinoma.

Ji L, Liang S, Cheng Y, Gao R, Yan W, Pang F Cancer Biomark. 2024; 40(3-4):319-342.

PMID: 39213052 PMC: 11380221. DOI: 10.3233/CBM-230407.

The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors.

Li P, Ma X, Gu X Front Cell Dev Biol. 2024; 12:1442193.

PMID: 39161590 PMC: 11330846. DOI: 10.3389/fcell.2024.1442193.

References

Yang W, Zeng X, Liu Z, Zhao Q, Tan Y, Gao J . Diet and liver cancer risk: a narrative review of epidemiological evidence. Br J Nutr. 2020; 124(3):330-340. DOI: 10.1017/S0007114520001208. View

Shan Y, Li P . Long Intergenic Non-Protein Coding RNA 665 Regulates Viability, Apoptosis, and Autophagy via the MiR-186-5p/MAP4K3 Axis in Hepatocellular Carcinoma. Yonsei Med J. 2019; 60(9):842-853. PMC: 6704017. DOI: 10.3349/ymj.2019.60.9.842. View

Chew V, Chen J, Lee D, Loh E, Lee J, Lim K . Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2011; 61(3):427-38. PMC: 3273680. DOI: 10.1136/gutjnl-2011-300509. View

Bruix J, Han K, Gores G, Llovet J, Mazzaferro V . Liver cancer: Approaching a personalized care. J Hepatol. 2015; 62(1 Suppl):S144-56. PMC: 4520430. DOI: 10.1016/j.jhep.2015.02.007. View

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

St Laurent G, Wahlestedt C, Kapranov P . The Landscape of long noncoding RNA classification. Trends Genet. 2015; 31(5):239-51. PMC: 4417002. DOI: 10.1016/j.tig.2015.03.007. View

Center M, Jemal A . International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011; 20(11):2362-8. DOI: 10.1158/1055-9965.EPI-11-0643. View

Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S . Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008; 129(3):428-37. DOI: 10.1016/j.clim.2008.08.012. View

van der Leun A, Thommen D, Schumacher T . CD8 T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020; 20(4):218-232. PMC: 7115982. DOI: 10.1038/s41568-019-0235-4. View

10.

Kopp F, Mendell J . Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018; 172(3):393-407. PMC: 5978744. DOI: 10.1016/j.cell.2018.01.011. View

11.

Anwanwan D, Singh S, Singh S, Saikam V, Singh R . Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188314. PMC: 6981221. DOI: 10.1016/j.bbcan.2019.188314. View

12.

Li W, Dong X, He C, Tan G, Li Z, Zhai B . LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2019; 38(1):183. PMC: 6499991. DOI: 10.1186/s13046-019-1177-0. View

13.

Lee K, Guerrero-Zotano A, Servetto A, Sudhan D, Lin C, Formisano L . Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nat Commun. 2020; 11(1):5488. PMC: 7599336. DOI: 10.1038/s41467-020-19291-x. View

14.

Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J . A Novel lncRNA, LINC00460, Affects Cell Proliferation and Apoptosis by Regulating KLF2 and CUL4A Expression in Colorectal Cancer. Mol Ther Nucleic Acids. 2018; 12:684-697. PMC: 6083012. DOI: 10.1016/j.omtn.2018.06.012. View

15.

Klingenberg M, Gross M, Goyal A, Polycarpou-Schwarz M, Miersch T, Ernst A . The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling. Hepatology. 2018; 68(5):1817-1832. DOI: 10.1002/hep.30102. View

16.

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

17.

Tarantelli C, Gaudio E, Arribas A, Kwee I, Hillmann P, Rinaldi A . PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clin Cancer Res. 2017; 24(1):120-129. DOI: 10.1158/1078-0432.CCR-17-1041. View

18.

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X . Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18(1):26. PMC: 6379961. DOI: 10.1186/s12943-019-0954-x. View

19.

Zhou Y, Huan L, Wu Y, Bao C, Chen B, Wang L . LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Cancer Lett. 2019; 469:399-409. DOI: 10.1016/j.canlet.2019.11.007. View

20.

Chew V, Tow C, Teo M, Wong H, Chan J, Gehring A . Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 2009; 52(3):370-9. DOI: 10.1016/j.jhep.2009.07.013. View